Patients with “small hepatocellular carcinoma” in special locations, patients with middle to late stage hepatocellular carcinoma with huge tumors, and patients with multiple metastatic lesions in stage IIIb or IV in pathological staging are often deprived of the opportunity of surgical treatment. Patients in the above situation should prefer argon-helium super-cooling knife minimally invasive treatment, which directly destroys the cellular structure of tumor tissue through physical freezing and thawing means in a short period of time, prompting necrosis and apoptosis of tumor tissue in the center of freezing, and closing small blood vessels for tumor supply. Combined with interventional treatment, the two can inhibit the growth of liver cancer in a short period of time for patients with giant liver cancer. Since most of the primary hepatocellular carcinomas are unresectable large hepatocellular carcinomas and are mostly accompanied by cancer thrombosis in the portal vein system inside and outside the liver. Therefore, after conventional radiotherapy, the recurrence rate is still as high as 60% within 1 year, and the 3-year survival rate is less than 30%, and extensive metastasis can occur within 2 months after surgery at the earliest. The recurrence of liver cancer after surgery mainly comes from the micro-metastasis of early liver cancer, so the recurrence prevention treatment after liver cancer surgery is very crucial. stop and control further tumor development and metastasis. It can address the subclinical metastasis which is difficult to be solved by conventional therapy, so as to further improve and consolidate the efficacy of liver cancer and reduce recurrence. According to clinical statistics, cellular immunotherapy can better prevent recurrence of hepatocellular carcinoma after surgery. 9 cases of stage IV patients had an average survival of 20 months after more than 3 cycles of treatment after surgery, and the recurrence rate was 22.2% within 1 year. Most of the patients showed improvement in self-conscious symptoms and significant improvement in quality of life. one patient with advanced hepatocellular carcinoma with lung metastasis achieved partial remission (PR) after CIK cell therapy, which was confirmed by imaging, and has survived for more than 2 years.